Oncotarget

Research Papers:

Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer

Takeo Kosaka _, Hiroshi Hongo, Yasumasa Miyazaki, Koshiro Nishimoto, Akira Miyajima & Mototsugu Oya

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2017; 8:87675-87683. https://doi.org/10.18632/oncotarget.21147

Metrics: PDF 380 views  |   HTML 1028 views  |   ?  


Abstract

Takeo Kosaka1, Hiroshi Hongo1, Yasumasa Miyazaki1, Koshiro Nishimoto2, Akira Miyajima3 and Mototsugu Oya1

1Department of Urology, Keio University School of Medicine, Tokyo, Japan

2Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan

3Department of Urology, Tokai University School of Medicine, Hiratsuka-shi, Japan

Correspondence to:

Takeo Kosaka, email: takemduro@gmail.com

Keywords: castration-resistant prostate cancer, cabazitaxel, ROS, SESN3

Received: April 04, 2017     Accepted: August 23, 2017     Published: September 21, 2017

ABSTRACT

Reactive oxygen species (ROS) production induced by taxanes in cancer cells may influence the taxane-induced cell death or the drug resistance. We investigated the correlation between the cytotoxic effect of taxanes and ROS production in human castration-resistant prostate cancer (CRPC) cell lines. Three human prostate cancer cell lines were treated with increasing concentrations of docetaxel or cabazitaxel in vitro. Cabazitaxel showed significantly higher cytotoxic efficacy than docetaxel in human CRPC cells, accompanied by elevated ROS production detected by FACS analysis. To investigate whether cabazitaxel-mediated cell death was caused by the ROS generation induced by cabazitaxel, we treated CRPC cells in the presence of antioxidant NAC. NAC reduced the cytotoxic effect induced by cabazitaxel. We found that ROS elimination by Sestrin-3 (SESN3) was significantly inhibited by cabazitaxel, but not by docetaxel. These results indicate higher sensitivity of human CRPC to cabazitaxel compared to docetaxel involves ROS production through inhibiting the expression of antioxidant enzyme SESN3.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21147